Drug interactions
Ofatumumab sc + Ruxolitinib
Severity: Moderate
Ofatumumab sc and Ruxolitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents impair immune function, so combined use may raise the risk of serious infections. Ofatumumab depletes B cells while ruxolitinib inhibits JAK signaling.
What this interaction means in plain words
Ofatumumab sc and Ruxolitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Additive immunosuppression through B-cell depletion and JAK inhibition.
What to do
Screen for active infection and hepatitis B before starting, and monitor for infection signs during combined therapy. Interrupt treatment if a serious infection develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ofatumumab sc and Ruxolitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ruxolitinib
Frequently asked questions
Can I take Ofatumumab sc with Ruxolitinib?
MediHelp rates the interaction as moderate. Ofatumumab sc and Ruxolitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both agents impair immune function, so combined use may raise the risk of serious infections. Ofatumumab depletes B cells while ruxolitinib inhibits JAK signaling.
How serious is the interaction between Ofatumumab sc and Ruxolitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Screen for active infection and hepatitis B before starting, and monitor for infection signs during combined therapy. Interrupt treatment if a serious infection develops.
What other medicines interact with Ruxolitinib?
MediHelp also lists interactions of Ruxolitinib with, for example, Atazanavir, Ceritinib, Chloramphenicol. The full list is on the Ruxolitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
